Bluebird Bio Inc (BLUE)

Nov 18, 2024

Layoff Tracker: Adaptimmune Downsizes by 33% in Strategic Realignment - BioSpace

Nov 18, 2024

Nov 18, 2024

Adoptive Cell Therapy Market Industry Insights: Market Size, - openPR

Nov 18, 2024

Nov 18, 2024

bluebird bio (NASDAQ:BLUE) Now Covered by StockNews.com - MarketBeat

Nov 18, 2024

Nov 17, 2024

B of A Securities Downgrades bluebird bio (BLUE) - MSN

Nov 17, 2024

Nov 16, 2024

bluebird bio Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance

Nov 16, 2024

Nov 15, 2024

Earnings Snapshot: bluebird bio reports mixed Q3, Q4 revenue outlook below consensus - MSN

Nov 15, 2024

Nov 15, 2024

JP Morgan Downgrades Gene Therapy Focused Bluebird Bio, Cites Limited Funding Options - AOL

Nov 15, 2024

Nov 15, 2024

Royal Bank of Canada Reaffirms "Sector Perform" Rating for bluebird bio (NASDAQ:BLUE) - MarketBeat

Nov 15, 2024

Nov 15, 2024

bluebird bio extends selloff as BofA and J.P. Morgan cut after Q3 results - MSN

Nov 15, 2024

Nov 15, 2024

bluebird bio downgraded by Bank of America, shares tumble - Proactive Investors USA

Nov 15, 2024

Nov 15, 2024

bluebird bio stock cut at BofA and J.P. Morgan (BLUE:NASDAQ) - Seeking Alpha

Nov 15, 2024

Nov 15, 2024

bluebird bio (NASDAQ:BLUE) Price Target Lowered to $2.00 at Barclays - MarketBeat

Nov 15, 2024

Nov 15, 2024

Bluebird bio stock plunges to 52-week low of $0.34 - Investing.com

Nov 15, 2024

Nov 15, 2024

Bluebird bio stock plunges to 52-week low of $0.34 By Investing.com - Investing.com UK

Nov 15, 2024

Nov 15, 2024

bluebird bio (NASDAQ:BLUE) Downgraded to "Neutral" Rating by Bank of America - MarketBeat

Nov 15, 2024

Nov 15, 2024

JPMorgan Chase & Co. Downgrades bluebird bio (NASDAQ:BLUE) to Underweight - MarketBeat

Nov 15, 2024

Nov 15, 2024

bluebird bio, Inc. (NASDAQ:BLUE) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 15, 2024

Nov 15, 2024

bluebird bio, Inc.'s (NASDAQ:BLUE) Revenues Are Not Doing Enough For Some Investors - Simply Wall St

Nov 15, 2024

Nov 15, 2024

Bluebird: Q3 Earnings Snapshot - Darien Times

Nov 15, 2024

Nov 15, 2024

bluebird bio Inc (BLUE) Q3 2024 Earnings Call Highlights: Naviga - GuruFocus.com

Nov 15, 2024

Nov 15, 2024

bluebird bio Inc (BLUE) Q3 2024 Earnings Call Highlights: Navigating Revenue Challenges and ... - Yahoo Finance

Nov 15, 2024

Nov 14, 2024

Bluebird bio Reports Q3 2024 Earnings and Future Outlook - TipRanks

Nov 14, 2024

Nov 14, 2024

bluebird bio Inc (BLUE) Quarterly 10-Q Report - Quartzy

Nov 14, 2024

Nov 14, 2024

Earnings call: Bluebird bio sees patient growth, aims for 2025 breakeven - Investing.com

Nov 14, 2024

Nov 14, 2024

bluebird bio Reports Third Quarter 2024 Results and Highlights Operational Progress and 2024 Guidance - citybiz

Nov 14, 2024

Nov 14, 2024

Bluebird bio says it needs cash to operate beyond March 2025 - The Business Journals

Nov 14, 2024

Nov 14, 2024

Cell and Gene Therapy Market to Grow by USD 6.56 Billion (2024-2028), Driven by Rising Prevalence of Chronic Diseases, AI-Powered Report Explores Market EvolutionTechnavio - The Malaysian Reserve

Nov 14, 2024

Nov 14, 2024

BLUE (bluebird bio) Price-to-Operating-Cash-Flow : (As of Nov. 14, 2024) - GuruFocus.com

Nov 14, 2024

Nov 14, 2024

Bluebird Bio (BLUE) Reports Q3 Loss, Lags Revenue Estimates - Yahoo Finance

Nov 14, 2024

Nov 14, 2024

Q3 2024 bluebird bio Inc Earnings Call Transcript - GuruFocus.com

Nov 14, 2024

Nov 14, 2024

bluebird bio Q3 Revenue Dips to $10.6M, Eyes Break-Even by 2025 Despite Losses | BLUE Stock News - StockTitan

Nov 14, 2024

Nov 14, 2024

Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size, - openPR

Nov 14, 2024

Nov 13, 2024

bluebird bio Q3 2024 Earnings Preview - MSN

Nov 13, 2024

Nov 13, 2024

Goldman Sachs Group Inc's Strategic Acquisition of Shares in blu - GuruFocus.com

Nov 13, 2024

Nov 13, 2024

Gene Therapy For Rare Disease Market Growth Demand, Segment - openPR

Nov 13, 2024

Nov 12, 2024

Eagle Pharmaceuticals Taps Former Bluebird Bio CFO Krawtschuk to Lead Finance | EGRX Stock News - StockTitan

Nov 12, 2024

Nov 10, 2024

bluebird bio (NASDAQ:BLUE) Earns Sell Rating from Analysts at StockNews.com - MarketBeat

Nov 10, 2024

Nov 07, 2024

bluebird bio Adjourns Meeting of Stockholders and Announces Third Quarter 2024 Results Call - BioSpace

Nov 07, 2024

Nov 06, 2024

bluebird bio expands incentive plan amid leadership changes - Investing.com India

Nov 06, 2024

Nov 06, 2024

Bluebird Bio’s Key Decisions and Shareholder Engagement in 2024 - TipRanks

Nov 06, 2024

Nov 06, 2024

bluebird bio expands incentive plan amid leadership changes By Investing.com - Investing.com UK

Nov 06, 2024

Nov 06, 2024

bluebird bio Delays Stock Split Vote, Faces Nasdaq Delisting Risk Amid Capital Needs | BLUE Stock News - StockTitan

Nov 06, 2024

Nov 06, 2024

What's Going On With Bluebird Bio Stock? - MSN

Nov 06, 2024

Nov 05, 2024

bluebird bio to Present Additional Long-Term Follow-up Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition - BioSpace

Nov 05, 2024

Nov 05, 2024

Bluebird bio stock plunges to 52-week low of $0.45 amid downturn - Investing.com Australia

Nov 05, 2024

Nov 05, 2024

Bluebird Bio to Present Groundbreaking 10-Year Gene Therapy Data at ASH Meeting | BLUE Stock News - StockTitan

Nov 05, 2024

Nov 05, 2024

BLUE (bluebird bio) Cyclically Adjusted FCF per Share : $-7.77 (As of Jun. 2024) - GuruFocus.com

Nov 05, 2024

Nov 05, 2024

Vanguard Group Inc's Strategic Acquisition of Shares in bluebird bio Inc - GuruFocus.com

Nov 05, 2024

Nov 02, 2024

StockNews.com Begins Coverage on bluebird bio (NASDAQ:BLUE) - MarketBeat

Nov 02, 2024

Oct 31, 2024

7 children given bluebird's Skysona developed blood cancer: study - MSN

Oct 31, 2024

Oct 31, 2024

bluebird bio (BLUE): Promising Gene Editing Stock with FDA-Approved Therapies - Insider Monkey

Oct 31, 2024

Oct 29, 2024

bluebird bio, Inc. (NASDAQ:BLUE) Receives $4.63 Consensus PT from Analysts - MarketBeat

Oct 29, 2024

Oct 26, 2024

The Ultimate Biotech Stock to Buy With $50 Right Now - The Motley Fool

Oct 26, 2024

Oct 25, 2024

bluebird bio (NASDAQ:BLUE) Receives New Coverage from Analysts at StockNews.com - MarketBeat

Oct 25, 2024